CRMD 财务： CorMedix Inc AI 分析

Q: CorMedix Inc 的关键财务报表是什么？

根据最新的财务报表（Form-10K），CorMedix Inc 的总资产为 $118，净损失为 $-17

Q: CRMD 的关键财务比率是什么？

CorMedix Inc 的流动比率是 3.47，净利 margin 为 -39.53，每股销售为 $0.73。

Q: CorMedix Inc 的收入按细分市场或地理位置如何划分？

CorMedix Inc 最大收入来源是 Drug，在最近的收益报告中收入为 43,472,170。就地区而言， United States 是 CorMedix Inc 的主要市场，收入为 43,472,170。

Q: CorMedix Inc 是否盈利？

不，根据最新的财务报表，CorMedix Inc 的净损失为 $-17

Q: CorMedix Inc 有负债吗？

是的，CorMedix Inc 的负债为 34

Q: CorMedix Inc 的流通股有多少？

CorMedix Inc 的总流通股为 64.41

主页

股票

CRMD

CRMD 财务

CorMedix Inc

$7.33

6.54%

$0.45

收盘价：Jan 21, 16:00:00 GMT-5

$7.41

1.21%

$0.08

盘后：Jan 21, 20:00:00 GMT-5

概述预测收益股息财务数据

关键数据

前收盘价

$6.88

开盘价

$6.85

当日区间

$6.82 - $7.41

52周范围

$5.6 - $17.43

交易量

2.7M

平均成交量

3.3M

每股收益（TTM）

2.05

股息收益率

市值

$584.5M

什么是 CRMD？

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 64 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The firm is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

功能特性

交易策略

资源

市场

收入

资产负债表

现金流量

年度

季度性

CRMD 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
营收	214	43	0	0	0	0
营收同比增长 (YoY)	1,682.99%	--	--	--	--	--
营收成本	15	3	0	0	0	0
毛利润	198	40	0	0	0	0
销售、一般及管理费用	82	58	35	20	16	13
研发	12	3	13	10	13	13
营业费用	94	62	48	30	29	27
其他非经营性收入 (费用)	-2	0	--	--	--	--
税前利润	107	-19	-46	-30	-29	-27
所得税费用	-55	-1	0	0	-1	-5
净利润	162	-17	-46	-29	-28	-22
净利润增长	-451.99%	-63%	59%	4%	27%	-49%
稀释后流通股数	86.21	58.87	50.9	40.27	37.67	28.56
股份同比变动 (YoY)	47%	16%	26%	7%	32%	18%
每股收益 (摊薄)	1.88	-0.3	-0.91	-0.74	-0.75	-0.77
每股收益增长率	-335%	-67%	23%	-1%	-3%	-56.99%
自由现金流	74	-50	-38	-24	-22	-22
每股自由现金流	--	--	--	--	--	--
毛利率	92.52%	93.02%	0%	0%	0%	0%
营业利润率	48.13%	-51.16%	0%	0%	0%	0%
净利率	75.7%	-39.53%	0%	0%	0%	0%
自由现金流利润率	34.57%	-116.27%	0%	0%	0%	0%
EBITDA	107	-22	-48	-30	-29	-27
EBITDA 利润率	50%	-51.16%	0%	0%	0%	0%
EBITDA 中的折旧与摊销	4	0	0	0	0	0
EBIT	103	-22	-48	-30	-29	-27
EBIT 利润率	48.13%	-51.16%	0%	0%	0%	0%
有效税率	-51.4%	5.26%	0%	0%	3.44%	18.51%

Follow-Up Questions

CorMedix Inc 的关键财务报表是什么？



CRMD 的关键财务比率是什么？



CorMedix Inc 的收入按细分市场或地理位置如何划分？



CorMedix Inc 是否盈利？



CorMedix Inc 有负债吗？



CorMedix Inc 的流通股有多少？



CorMedix Inc（CRMD）价格

CRMD 股价走势图